SOPHiA GENETICS Q4 Revenue Up 22% to $21.7M, Adjusted Gross Margin 74.2%
SOPHiA GENETICS reported Q4 2025 revenue of $21.7 million, up 22% year-over-year, and full-year revenue of $77.3 million, up 19%. Adjusted gross margin expanded to 74.2% in FY 2025 while IFRS net loss grew 26% to $79.0 million and adjusted EBITDA loss rose 3% to $41.5 million.
1. Q4 and Full Year 2025 Financial Results
In Q4 2025, SOPHiA GENETICS generated $21.7 million in revenue, a 22% increase year-over-year, with reported gross margin of 67.7% and adjusted gross margin of 73.9%. IFRS net loss widened 27% to $19.2 million and adjusted EBITDA loss increased 9% to $9.9 million. For the full year, revenue reached $77.3 million (up 19%), reported gross margin held at 67.4% while adjusted gross margin rose to 74.2%, IFRS net loss grew 26% to $79.0 million and adjusted EBITDA loss climbed 3% to $41.5 million.
2. Platform Usage and Customer Growth
The SOPHiA DDM platform processed over 391,000 analyses in 2025, including more than 105,000 in Q4. Core genomics customers increased to 528 from 472 a year earlier, with net dollar retention improving to 115% and churn falling. SOPHiA GENETICS added a record 124 new customers in 2025, with average contract value up approximately 120% year-over-year.
3. Major U.S. Contracts and Application Expansion
The company signed two large U.S. integrated health systems expected to conduct 60,000 analyses annually starting H2 2026, and a strategic collaboration with MD Anderson to co-develop multimodal oncology tests. Liquid Biopsy analyses exceeded 7,500 for the year, with over 70 customers on MSK-ACCESS® and 21 on MSK-IMPACT® and MSK-IMPACT® Flex.
4. Liquidity and Future Outlook
SOPHiA GENETICS raised $15.5 million net through its ATM program at an average price of $5.12 per share and expanded its credit facility by $25 million. The company expects U.S. market execution, Liquid Biopsy expansion and BioPharma partnerships to drive 2026 growth and anticipates increased operating leverage as the platform scales.